Clinical trials: Atomoxetine Hydrochloride
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Neurogenic Orthostatic Hypotension
Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
This was a randomized, open-label clinical trial. We will enroll patients with symptomatic neurogenic OH and randomize them to 1 of 2 treatments: (1) midodrine only, (2) atomoxetine only.
- Trial name
- NCT03350659
- Testing
- Midodrine, Atomoxetine
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Attention Deficit Hyperactivity Disorder
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children…
- Trial name
- NCT00471354
- Testing
- Atomoxetine
- Where
- 8 sites in China, South Korea and 1 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Methamphetamine Dependence
Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
The purpose of this study is to examine the ability of atomoxetine compared to placebo to increase time to relapse in methamphetamine dependent volunteers.
- Trial name
- ATM (NCT01557569)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas